The distribution, release kinetics, and biocompatibility of Triamcinolone injected and dispersed in silicone oil

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 5, 2009, Pages 2337-2343

  Spitzer, Martin S ^a   Kaczmarek, Radoslaw T ^a   Yoeruek, Efdal ^a   Petermeier, Katrin ^a   Wong, David ^b,c   Heimann, Hanno ^b   Jaissle, Gesine B ^a   Bartz Schmidt, Karl U ^a   Szurman, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; SILICONE OIL; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG RELEASE; EPITHELIUM CELL; MONOLAYER CULTURE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; SCANNING ELECTRON MICROSCOPY; SEDIMENT; SIMULATION; SPECTROPHOTOMETRY; VITREOUS BODY; BIOLOGICAL MODEL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; HUMAN; INJECTION; MATERIALS TESTING; METABOLISM; TISSUE DISTRIBUTION; ULTRASTRUCTURE;

CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; MODELS, BIOLOGICAL; RETINAL GANGLION CELLS; RETINAL PIGMENT EPITHELIUM; SILICONE OILS; TISSUE DISTRIBUTION; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 65549107419     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2471     Document Type: Article

References (28)

1. Scott IU, Flynn HW Jr, Murray TG, et al. Outcomes of complex retinal detachment repair using 1000-vs 5000-centistoke silicone oil. Arch Ophthalmol. 2005;123:437-438.
2. Castellarin A, Grigorian R, Bhagat N, et al. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol. 2003; 87:318-321.
3. Lewis H, Burke JM, Abrams GW, et al. Perisilicone proliferation after vitrectomy for proliferative vitreoretinopathy. Ophthalmology. 1988;95:583-591.
4. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial: Daunomycin Study Group. Am J Ophthalmol. 1998;126:550-559.
5. Asaria RA, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179-1183.
6. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979; 77:171-180.
7. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816.
8. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772.
9. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920-927.
10. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61.
11. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
12. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study. Eye. 2005;19:163-170.
13. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131:468-471.
14. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067.
15. Jonas JB, Söfker A, Degenring R. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2003;13:468-473.
16. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005; 40:598-604.
17. Cheema RA, Peyman GA, Fang T, et al. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging. 2007;38:365-370.
18. Hernaez-Ortega MC, Soto-Pedre E. A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging. 2005;35:350-351.
19. Herbert E, Stappler T, Wetterqvist C, Williams R, Wong D. Tamponade properties of double-filling with perfluorohexyloctane and silicone oil in a model eye chamber. Graefes Arch Clin Exp Ophthalmol. 2004;242:250-254.
20. Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung surfactant. J Control Release. 2000;65:43-47.
21. Ungphaiboon S, Nittayananta W, Vuddhakul V, et al. Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. Am J Health Syst Pharm. 2005;62:485-491.
22. Jonas JB. Concentration of intravitreally injected triamcinolone in intraocular silicone oil. Br J Ophthalmol. 2002;86:1450-1451.
23. Yeung CK, Chan KP, Chiang SWY, Pang CP, Lam DSC. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci. 2003;44:5293-5300.
24. Szurman P, Kaczmarek R, Spitzer MS, et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res. 2006;83:584-592.
25. Szurman P, Sierra A, Kaczmarek R, et al. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res. 2007;85:44-53.
26. Jonas JB, Sofker A, Hayler J, Degenring RF. Intravitreal crystalline triamcinolone acetonide as an additional tool in pars plana vitrectomy for complicated proliferative vitreoretinopathy? Acta Opthalmol Scand. 2003;10:663-665.
27. Xu J, Heys JJ, Barocas VH, Randolph TW. Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm Res. 2000;17:664-669.
28. Stay MS, Xu J, Randolph TW, Barocas VH. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm Res. 2003;20:96-102.